AGN 190584

Drug Profile

AGN 190584

Alternative Names: AGN 190584

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator Allergan
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 01 May 2016 Allergan initiates a phase II trial for Presbyopia (Combination therapy) in USA (NCT02780115)
  • 01 Apr 2016 Phase-II clinical trials in Presbyopia (Combination therapy) in USA (Ophthalmic) (NCT02595528)
  • 06 Nov 2015 Allergan plans a phase II trial for Presbyopia (Combination therapy) in USA (NCT02595528)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top